COTQF (Cotinga Pharmaceuticals) Momentum Rank : 0 (As of Sep. 24, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Momentum Rank?

Cotinga Pharmaceuticals has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Cotinga Pharmaceuticals Momentum Rank Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Cotinga Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1

Website

http://www.cotingapharma.com

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals Headlines

From GuruFocus

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire • 05-22-2019

Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results

By GlobeNewswire GlobeNewswire • 04-03-2018